Merck in Talks to Acquire Revolution Medicines in USD 28-32 Billion Oncology Deal

Other large pharmaceutical groups were still circling the biotech and another suitor might yet prevail, the FT report said, adding a transaction is not ​a foregone conclusion.

A potential buyout of Revolution ​by Merck would mark the biggest deal in the pharmaceutical sector ‌in nearly ‍three years since Pfizer's $43 billion takeover of cancer biotech ‍Seagen.

Revolution Medicines and Merck did not immediately respond to Reuters' ‌requests for comment.

Merck, which is set to lose patents for its blockbuster cancer treatment Keytruda later this decade, has nearly tripled its late-stage pipeline since 2021 through in-house development and big deals such as the $11.5 billion purchase of Acceleron for pulmonary arterial hypertension drug Winrevair.

A deal with Revolution could give Merck access to its experimental ‍drug daraxonrasib, which is in late-stage trials and has won a fast-track review voucher from the U.S. Food ‍and Drug Administration.

The ⁠drug is designed to ⁠target multiple mutations in the RAS genes, which are common drivers of major cancers, including certain pancreatic, lung and colorectal cancers.

Mizuho analysts estimate more than $10 billion in potential risk-adjusted sales globally from Revolution's portfolio of RAS inhibitors by 2035.

The FT article came a day after the Wall Street Journal reported that AbbVie was in advanced talks to buy Revolution, a claim the drugmaker later denied.